6589 Taikang Bio's Biosimilar Drug 'EIRGASUN vial 420 mg' Approved for National Health Insurance Coverage by NHIA
Taikang Bio's (6589) biosimilar drug 'EIRGASUN vial 420 mg' has been approved by Taiwan's National Health Insurance Administration (NHIA) under the Ministry of Health and Welfare for inclusion in National Health Insurance coverage. It is indicated for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The price is NT$24,240 per vial, effective from June 1, 2026.
📋 Article Processing Timeline
- 📰 Published: May 16, 2026 at 12:57
- 🔍 Collected: May 16, 2026 at 12:57 (0 min after Published)
- 🤖 AI Analyzed: May 16, 2026 at 14:39 (1h 42m after Collected)
Date of Announcement: 2026/05/16
Date of Occurrence: 2026/05/15
Time of Occurrence: 14:19:34
Company Code: 6589
Company Name: Taikang Bio
Subject: Our company's biosimilar drug 'EIRGASUN vial 420 mg' has been approved for inclusion in National Health Insurance coverage by the National Health Insurance Administration, Ministry of Health and Welfare.
Applicable clause: Article 51
Date of event: 2026/05/15
Explanation:
1. Date of occurrence of the event: 2026/05/15
2. Company name: Taikang Biotechnology Co., Ltd.
3. Relationship with the company (please enter 'our company' or 'subsidiary'): Our company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence:
(1) Our company's biosimilar drug 'EIRGASUN vial 420 mg', used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer, has been approved for inclusion in the National Health Insurance coverage by the National Health Insurance Administration, Ministry of Health and Welfare. The approved payment price is NT$24,240 per vial, effective from June 1, 2026.
(2) According to the 2024 medical order declaration data published by the National Health Insurance Administration, the total annual declaration volume for Trastuzumab 420mg to 440mg specifications reached 30,942 vials.
6. Countermeasures: Release of material information.
7. Other matters that should be stated (if the subject of the event or resolution is a public company or above, this material information also complies with Article 7, Paragraph 9 of the Enforcement Rules of the Securities Exchange Act regarding matters that have a significant impact on shareholders' equity or securities prices): None
Date of Occurrence: 2026/05/15
Time of Occurrence: 14:19:34
Company Code: 6589
Company Name: Taikang Bio
Subject: Our company's biosimilar drug 'EIRGASUN vial 420 mg' has been approved for inclusion in National Health Insurance coverage by the National Health Insurance Administration, Ministry of Health and Welfare.
Applicable clause: Article 51
Date of event: 2026/05/15
Explanation:
1. Date of occurrence of the event: 2026/05/15
2. Company name: Taikang Biotechnology Co., Ltd.
3. Relationship with the company (please enter 'our company' or 'subsidiary'): Our company
4. Mutual shareholding ratio: Not applicable
5. Reason for occurrence:
(1) Our company's biosimilar drug 'EIRGASUN vial 420 mg', used for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer, has been approved for inclusion in the National Health Insurance coverage by the National Health Insurance Administration, Ministry of Health and Welfare. The approved payment price is NT$24,240 per vial, effective from June 1, 2026.
(2) According to the 2024 medical order declaration data published by the National Health Insurance Administration, the total annual declaration volume for Trastuzumab 420mg to 440mg specifications reached 30,942 vials.
6. Countermeasures: Release of material information.
7. Other matters that should be stated (if the subject of the event or resolution is a public company or above, this material information also complies with Article 7, Paragraph 9 of the Enforcement Rules of the Securities Exchange Act regarding matters that have a significant impact on shareholders' equity or securities prices): None